Published in Mol Cell Proteomics on April 23, 2014
Beyond BRAF: where next for melanoma therapy? Br J Cancer (2014) 1.26
Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma. Mol Cell Proteomics (2015) 1.02
Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res (2014) 0.87
Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma. Proteomics (2014) 0.82
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. Oncotarget (2016) 0.80
Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays. Mol Cell Proteomics (2015) 0.79
Advances in targeted proteomics and applications to biomedical research. Proteomics (2016) 0.79
Change or die: targeting adaptive signaling to kinase inhibition in cancer cells. Biochem Pharmacol (2014) 0.78
Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods (2015) 0.77
Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma. Melanoma Res (2014) 0.77
Parsing interindividual drug variability: an emerging role for systems pharmacology. Wiley Interdiscip Rev Syst Biol Med (2015) 0.76
The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors. Pigment Cell Melanoma Res (2015) 0.76
PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach. Oncotarget (2016) 0.75
A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research. Front Oncol (2017) 0.75
Proteomic Findings in Melanoma. J Proteomics Bioinform (2016) 0.75
Inhibition of PI3K/Akt/mTOR signaling in PI3KR2-overexpressing colon cancer stem cells reduces tumor growth due to apoptosis. Oncotarget (2016) 0.75
The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations. Invest New Drugs (2015) 0.75
Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 45.46
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature (2010) 18.69
Skyline: an open source document editor for creating and analyzing targeted proteomics experiments. Bioinformatics (2010) 13.35
Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS. Proc Natl Acad Sci U S A (2003) 10.82
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature (2011) 10.77
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol (2009) 9.67
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Targeted cancer therapy. Nature (2004) 7.81
HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol (2010) 7.16
Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer (2010) 6.81
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell (2011) 6.74
Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci U S A (2007) 4.80
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res (2011) 4.80
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov (2013) 4.39
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol (2013) 4.26
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer. Cell (2012) 3.77
Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition. Cell (2012) 3.44
Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas. Cancer Cell (2012) 3.37
Absolute quantification of the model biomarker prostate-specific antigen in serum by LC-Ms/MS using protein cleavage and isotope dilution mass spectrometry. J Proteome Res (2004) 2.85
A small molecule inhibitor of inducible heat shock protein 70. Mol Cell (2009) 2.63
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. J Clin Oncol (2013) 2.51
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res (2011) 2.43
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms. Clin Cancer Res (2012) 2.31
Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. J Clin Invest (2013) 2.11
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res (2007) 2.06
The HSP70 family and cancer. Carcinogenesis (2013) 2.06
Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal (2012) 1.95
Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma. Clin Cancer Res (2008) 1.94
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem Pharmacol (2011) 1.59
Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Nat Methods (2013) 1.54
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl (2011) 1.25
Quantification of beta-catenin signaling components in colon cancer cell lines, tissue sections, and microdissected tumor cells using reaction monitoring mass spectrometry. J Proteome Res (2010) 1.20
NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene (2012) 1.15
A modified HSP70 inhibitor shows broad activity as an anticancer agent. Mol Cancer Res (2013) 1.14
Platform for establishing interlaboratory reproducibility of selected reaction monitoring-based mass spectrometry peptide assays. J Proteome Res (2010) 1.13
Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol (2011) 1.12
Molecular pathways: targeting hsp90--who benefits and who does not. Clin Cancer Res (2012) 1.04
Absolute quantification of proteins in solutions and in polyacrylamide gels by mass spectrometry. Anal Chem (2004) 1.03
Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J Proteome Res (2012) 1.01
Activity of the heat shock protein 90 inhibitor ganetespib in melanoma. PLoS One (2013) 0.97
Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer? Clin Cancer Res (2011) 0.95
Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation. Cell Cycle (2012) 0.94
Monitoring a nuclear factor-κB signature of drug resistance in multiple myeloma. Mol Cell Proteomics (2011) 0.86